Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a Study to Evaluate the Kappa Opioid Receptor As a Target for the Treatment of Mood and Anxiety Spectrum Disorders by Evaluation of Whether CERC-501 Engages Key Neural Circuitry Related to the Hedonic Response

NCT02218736 is registered in ClinicalTrials.gov with Duke University as lead sponsor.

NCT NCT02218736
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02218736 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a Study to Evaluate the Kappa Opioid Receptor As a Target for the Treatment of Mood and Anxiety Spectrum Disorders by Evaluation of Whether CERC-501 Engages Key Neural Circuitry Related to the Hedonic Response
Lead sponsor
Duke University
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2015
Completion date
December 1, 2017
Enrollment
163 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

anxiety disorders (or anxiety and phobic neuroses)